Pfizer will Co-promote Takeda Diabetes Drug

Pfizer has taken on the job of co-promoting a diabetes drug in China for Takeda Pharmaceutical Company. Actos® (pioglitazone HCl), an oral treatment for diabetes 2, produces over $4 billion of annual revenues for Takeda worldwide. The agreement will be in force until 2020 and pays Pfizer a fixed percentage of sales revenue. More details... Stock Symbol: (NYSE: PFE)